

Christopher Murray

Pharma International

Roche Principal to the Accelerating Access Initiative

Increasing Access to Medicines

Roche's long-term strategy

- Pursue solutions that are sustainable and can have long-term impact
- Roche believes its efforts to increase access to its medicines should be concentrated where they will benefit people in greatest need
- Roche prioritises initiatives towards a broad policy level
 - designed for greatest potential to benefit people in Least Developed Countries (defined by UN)
 - extended to all sub-Saharan Africa for HIV/AIDS

Increasing Access to Medicines

Our patent policy

- **No patents** for any of our medicines - **across all disease areas**
- will be filed in the world`s Least Developed Countries
- Roche will **not file** patents on new or investigational HIV/AIDS medicines in sub-Saharan Africa and Least Developed Countries
- Roche will **not act** against infringement of patents Roche holds on HIV/AIDS drugs in these countries

Increasing Access to Medicines

Our pricing policy

- **No profit prices** from Roche Basel on HIV protease inhibitors – Invirase and Viracept to sub-Saharan Africa and Least Developed Countries
- Roche no profit prices are significantly lower than those of generic versions
- Roche offers reduced prices for direct supplies of Invirase and Viracept from Basel to low income and lower middle income countries

Roche No Profit Pricing and Patent policies apply to

- More than 26 million people living with HIV/AIDS
- 2/3 of all people living with HIV/AIDS worldwide

(WHO, December 2003. AIDS epidemic update)

Malaria and Chagas

Roche's commitment

- Chagas (disease affecting 18 million people in South America)
 - Roche donated the rights and the technology to manufacture its medicine Benzonidazole to Brazilian government in 2003
- Roche made technical information available of our antimalarials to WHO to:
 - share knowledge
 - increase pace of research, development and affordability of much needed new antimalarials and new treatment strategies
- Collaboration with Medicines for Malaria Venture resulted in provision of a potential new malaria drug to a generic company for development and delivery, without compensation to Roche
- Publicizes patent status on antimalarials

Phelophepa – The Train of Hope

Clinic on tracks



Phelophepa – The Train of Hope

Healthcare to rural South Africa

- “Phelophepa” means “good ,clean health” (combination of the languages Sotho and Tswana)
- Founded in 1994 by Transnet
- Renders basic healthcare and educational services to rural communities in South Africa with no access to healthcare
- So far, Phelophepa has reached more than one million people

Phelophepa – The Train of Hope

Fact sheet

- 16 coaches, 339 metres, over 600 tons
- unique power coach generating power sufficient to supply a small town for two weeks
- fully equipped for general, dental, eye and psychiatric care
- train is underway 36 weeks of every year
- staff consists of 14 employees and around 40 students from various fields of medicine

Phelophepa – The Train of Hope

Roche's involvement

- First healthcare company to sponsor the train financially since its inception in 1994
- By 2001, Roche assumed full responsibility of the health clinic which was expanded to two coaches (salaries, educational and training services, equipment, outreach and school health programs)
- In 2003 Roche increased its support for Phelophepa; the additional financial resources were used for a new oncology and diabetes unit; at the same time, significant improvements were made to medical care for school children.



Roche